iRadimed (IRMD) Competitors $73.00 +3.00 (+4.29%) Closing price 08/12/2025 04:00 PM EasternExtended Trading$73.04 +0.05 (+0.06%) As of 08/12/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRMD vs. PRCT, WRBY, LIVN, EYE, LMAT, CNMD, LQDA, ENOV, AORT, and CDREShould you be buying iRadimed stock or one of its competitors? The main competitors of iRadimed include PROCEPT BioRobotics (PRCT), Warby Parker (WRBY), LivaNova (LIVN), National Vision (EYE), LeMaitre Vascular (LMAT), CONMED (CNMD), Liquidia Technologies (LQDA), Enovis (ENOV), Artivion (AORT), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. iRadimed vs. Its Competitors PROCEPT BioRobotics Warby Parker LivaNova National Vision LeMaitre Vascular CONMED Liquidia Technologies Enovis Artivion Cadre iRadimed (NASDAQ:IRMD) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk. Does the media refer more to IRMD or PRCT? In the previous week, PROCEPT BioRobotics had 21 more articles in the media than iRadimed. MarketBeat recorded 26 mentions for PROCEPT BioRobotics and 5 mentions for iRadimed. iRadimed's average media sentiment score of 0.73 beat PROCEPT BioRobotics' score of 0.01 indicating that iRadimed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 2 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, IRMD or PRCT? iRadimed has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, PROCEPT BioRobotics has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Do analysts prefer IRMD or PRCT? iRadimed presently has a consensus target price of $72.00, indicating a potential downside of 1.37%. PROCEPT BioRobotics has a consensus target price of $74.88, indicating a potential upside of 93.98%. Given PROCEPT BioRobotics' higher probable upside, analysts clearly believe PROCEPT BioRobotics is more favorable than iRadimed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRadimed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00PROCEPT BioRobotics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78 Is IRMD or PRCT more profitable? iRadimed has a net margin of 26.61% compared to PROCEPT BioRobotics' net margin of -30.60%. iRadimed's return on equity of 23.30% beat PROCEPT BioRobotics' return on equity.Company Net Margins Return on Equity Return on Assets iRadimed26.61% 23.30% 20.62% PROCEPT BioRobotics -30.60%-23.73%-17.34% Which has stronger valuation and earnings, IRMD or PRCT? iRadimed has higher earnings, but lower revenue than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioiRadimed$77.64M11.96$19.23M$1.6245.06PROCEPT BioRobotics$224.50M9.57-$91.41M-$1.55-24.90 Do insiders & institutionals have more ownership in IRMD or PRCT? 92.3% of iRadimed shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 36.8% of iRadimed shares are held by company insiders. Comparatively, 17.4% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryiRadimed beats PROCEPT BioRobotics on 11 of the 16 factors compared between the two stocks. Get iRadimed News Delivered to You Automatically Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRMD vs. The Competition Export to ExcelMetriciRadimedMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$890.40M$6.91B$5.49B$9.69BDividend Yield0.97%1.33%4.64%4.14%P/E Ratio45.0624.8530.4025.31Price / Sales11.9666.00444.45101.55Price / Cash44.2421.2037.7258.50Price / Book9.855.598.306.01Net Income$19.23M$176.29M$3.26B$265.10M7 Day Performance3.81%1.71%1.53%1.39%1 Month Performance26.80%-1.33%3.73%2.43%1 Year Performance65.98%11.11%41.02%24.74% iRadimed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRMDiRadimed4.2662 of 5 stars$73.00+4.3%$72.00-1.4%+65.9%$890.40M$77.64M45.06110PRCTPROCEPT BioRobotics3.4014 of 5 stars$49.60-0.7%$84.13+69.6%-39.0%$2.76B$249.12M-29.18430Trending NewsEarnings ReportAnalyst RevisionWRBYWarby Parker1.9688 of 5 stars$24.47+3.7%$23.13-5.5%+87.6%$2.47B$771.32M-203.883,780LIVNLivaNova2.0317 of 5 stars$42.76+4.0%$59.29+38.6%+16.7%$2.24B$1.25B-10.452,900Positive NewsEarnings ReportEYENational Vision2.8695 of 5 stars$25.07+3.6%$24.18-3.5%+123.2%$1.91B$1.82B-75.9713,411Positive NewsEarnings ReportLMATLeMaitre Vascular2.1669 of 5 stars$84.36+4.1%$97.83+16.0%+15.0%$1.83B$219.86M42.61490CNMDCONMED4.3847 of 5 stars$53.46+2.2%$59.80+11.9%-18.1%$1.62B$1.31B15.153,900Dividend AnnouncementLQDALiquidia Technologies2.9688 of 5 stars$19.48+10.2%$26.89+38.0%+97.4%$1.51B$14M-12.3350Trending NewsEarnings ReportOptions VolumeGap UpENOVEnovis3.8565 of 5 stars$26.61+3.4%$55.60+109.0%-32.2%$1.47B$2.11B-1.917,367News CoverageEarnings ReportAnalyst RevisionAORTArtivion3.0179 of 5 stars$32.06+3.7%$32.40+1.1%+73.9%$1.32B$388.54M-64.121,600Earnings ReportCDRECadre3.775 of 5 stars$33.09+2.3%$37.50+13.3%-12.7%$1.31B$567.56M34.832,284Analyst Revision Related Companies and Tools Related Companies PRCT Competitors WRBY Competitors LIVN Competitors EYE Competitors LMAT Competitors CNMD Competitors LQDA Competitors ENOV Competitors AORT Competitors CDRE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRMD) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRadimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share iRadimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access